Amniotic stem cell treatment for calciphylaxis
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-phase study tests a stem cell therapy made from amniotic (placenta) tissue for people with calciphylaxis. If you qualify, the goal is to see whether this treatment is safe and potentially helpful for this rare, painful condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- A doctor has diagnosed you with calciphylaxis (including people with chronic kidney disease, with or without regular dialysis).
- You are willing to sign the study consent form.
- You are not currently pregnant and are not breastfeeding (and if you could become pregnant, this must be addressed).
- You have not taken part in another drug study within the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a rare condition called calciphylaxis (hardening of small blood vessels) that can happen in people with chronic kidney disease. It aims to learn more about what causes it and how to help those affected.
This study collects and stores information from people with calciphylaxis, a serious condition that causes painful skin lesions. It may help researchers learn more about the disease and improve future care.
This Phase 3 study is for adults on regular dialysis who have a new calciphylaxis ulcer. It tests a better way to give and use treatment guidance so ulcers may improve with clearer, more consistent care.
This study tests a new drug called EPN-701 for calciphylaxis, a serious condition where calcium deposits damage blood vessels and skin, causing painful sores. If you have this condition and are on regular dialysis, this trial may help reduce your pain and heal your wounds.
This trial tests a drug called tocilizumab (an IL-6 blocker) for people with calciphylaxis, a painful skin condition linked to kidney disease. The goal is to see if the drug can reduce inflammation and improve skin sores.
This study tests whether a single infusion of stem cells from bone marrow is safe for people with chronic kidney disease (CKD). It aims to see if this treatment can help slow kidney function loss.
Hear when a new Calciphylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.